2025-10-30
FOXC1: The GPS for Capecitabine in TNBC?
Oncology
By Ana Espino | Published on october 30, 2025 | 3 min read
Triple-negative breast cancer (TNBC) is an aggressive form of the disease, often diagnosed in young women, that does not respond to hormone therapy or HER2-targeted treatments. Therapeutic options are mainly limited to cytotoxic chemotherapy, which shows variable efficacy and notable side effects. Among the available agents, capecitabine is widely prescribed as adjuvant therapy or for recurrent disease, but its clinical benefit varies considerably between patients.
One of the main challenges in TNBC lies in its biological heterogeneity: molecular profiles differ greatly, making it difficult to predict treatment response. In this context, identifying reliable biomarkers to guide therapeutic decisions is essential.
This study was therefore initiated to evaluate the potential of the transcription factor FOXC1 as a predictive biomarker of response to capecitabine, by analyzing its expression in tumor samples and correlating it with clinical outcomes.
The study focused on a cohort of patients with TNBC treated with capecitabine in the adjuvant or metastatic setting. FOXC1 expression was assessed by immunohistochemistry on tumor samples, then correlated with clinical response data, progression-free survival (PFS), and overall survival (OS). This approach aimed to explore the predictive value of FOXC1 in relation to capecitabine efficacy.
The results showed that tumors with high FOXC1 expression responded significantly better to capecitabine. These patients demonstrated higher objective response rates, longer response durations, and improved PFS and OS. The findings confirm that FOXC1 expression is an independent predictive factor for response to capecitabine, even after adjustment for other clinical variables.
Triple-negative breast cancer remains an aggressive disease with a poor prognosis, few targeted treatment options, and a high risk of relapse. One of the key current challenges is identifying biomarkers that can guide chemotherapy use—helping to avoid unnecessary treatments and optimize response rates.
In this context, the present study evaluated FOXC1 expression as a predictive marker of capecitabine efficacy in patients with TNBC treated in the adjuvant setting. The analysis indicates that FOXC1 is a strong predictor of response to capecitabine, independent of other clinical factors. It may influence tumor sensitivity to this treatment, although the underlying mechanisms remain unclear. This biomarker could therefore help identify patients most likely to benefit from capecitabine, while sparing others from ineffective therapy.
However, some limitations remain, and further research is warranted. Additional studies—including prospective validation, functional analyses of FOXC1, and stratified clinical trials—are needed to confirm its value as a precision medicine tool in TNBC.
Read next:
About the author – Ana Espino
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.
Triple-negative breast cancer (TNBC) is an aggressive form of the disease, often diagnosed in young women, that does not respond to hormone therapy or HER2-targeted treatments. Therapeutic options are mainly limited to cytotoxic chemotherapy, which shows variable efficacy and notable side effects. Among the available agents, capecitabine is widely prescribed as adjuvant therapy or for recurrent disease, but its clinical benefit varies considerably between patients.
One of the main challenges in TNBC lies in its biological heterogeneity: molecular profiles differ greatly, making it difficult to predict treatment response. In this context, identifying reliable biomarkers to guide therapeutic decisions is essential.
This study was therefore initiated to evaluate the potential of the transcription factor FOXC1 as a predictive biomarker of response to capecitabine, by analyzing its expression in tumor samples and correlating it with clinical outcomes.
Can FOXC1 predict who benefits from capecitabine?
The study focused on a cohort of patients with TNBC treated with capecitabine in the adjuvant or metastatic setting. FOXC1 expression was assessed by immunohistochemistry on tumor samples, then correlated with clinical response data, progression-free survival (PFS), and overall survival (OS). This approach aimed to explore the predictive value of FOXC1 in relation to capecitabine efficacy.
The results showed that tumors with high FOXC1 expression responded significantly better to capecitabine. These patients demonstrated higher objective response rates, longer response durations, and improved PFS and OS. The findings confirm that FOXC1 expression is an independent predictive factor for response to capecitabine, even after adjustment for other clinical variables.
Toward truly personalized chemotherapy
Triple-negative breast cancer remains an aggressive disease with a poor prognosis, few targeted treatment options, and a high risk of relapse. One of the key current challenges is identifying biomarkers that can guide chemotherapy use—helping to avoid unnecessary treatments and optimize response rates.
In this context, the present study evaluated FOXC1 expression as a predictive marker of capecitabine efficacy in patients with TNBC treated in the adjuvant setting. The analysis indicates that FOXC1 is a strong predictor of response to capecitabine, independent of other clinical factors. It may influence tumor sensitivity to this treatment, although the underlying mechanisms remain unclear. This biomarker could therefore help identify patients most likely to benefit from capecitabine, while sparing others from ineffective therapy.
However, some limitations remain, and further research is warranted. Additional studies—including prospective validation, functional analyses of FOXC1, and stratified clinical trials—are needed to confirm its value as a precision medicine tool in TNBC.
Read next:
About the author – Ana Espino
PhD in Immunology, specialized in Virology
Last press reviews
Triple-negative: a new targeted weapon?
By Ana Espino | Published on October 28, 2025 | 3 min read<br>
Rehabilitation, an often underestimated lever
By Ana Espino | Published on October 27, 2025 | 3 min read<br>
What if physical exercise were the key to clearing “chemo brain” after breast cancer?
By Lila Rouland | Published on October 27, 2025 | 3 min read<br><br>...